|Dr. Howard J. Verrico Ph.D., M.D.||Founder, Chairman, CEO & Sec.||245.2k||N/A||1961|
|Mr. Christopher D. Hopton||CFO & Director||212.6k||N/A||1966|
|Dr. GÃ©raldine Deliencourt-Godefroy||Chief Scientific Officer & Director||252.39k||N/A||N/A|
|Ms. Michelle Seltenrich MBA||VP of Operations||N/A||N/A||N/A|
|Dr. Brett A. Premack Ph.D.||Scientific Consultant||N/A||N/A||N/A|
Sirona Biochem Corp. develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. The company develops programs in the areas of diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Sirona Biochem Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.